Acceleron Pharma

Investors/Media

Press Releases

Date Title and Summary View
Toggle Summary Acceleron Announces Appointment of Dr. Karen Smith to its Board of Directors and Departure of Terrance McGuire
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN) today announced the appointment of the experienced biopharmaceutical executive, Karen Smith , M.D., Ph.D., to its board of directors and the departure of Terrance McGuire , effective November 15, 2017 .
View HTML
Toggle Summary Acceleron Announces Preclinical Results in Pulmonary Arterial Hypertension at the American Heart Association 2017 Scientific Sessions
- Preclinical results show potential first-in-class disease-modifying properties of sotatercept in pulmonary arterial hypertension - - Company expects to initiate a Phase 2 trial in 1H 2018 - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical
View HTML
Toggle Summary Acceleron Pharma Reports Third Quarter 2017 Operational and Financial Results
-Presented vision and strategic focus in hematological, neuromuscular, and pulmonary diseases at September R&D Day- -Obtained the rights to fund, develop, and lead global commercialization of sotatercept in pulmonary arterial hypertension; robust preclinical results show potential for
View HTML
Toggle Summary Acceleron to Present Clinical Presentations at the 59th American Society of Hematology Annual Meeting and Exposition
- Presentations to highlight efficacy, duration of response, and long-term safety results from ongoing Phase 2 studies in myelodysplastic syndromes and myelofibrosis - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and
View HTML
Toggle Summary Acceleron to Webcast Third Quarter 2017 Financial Results on November 7, 2017
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will host a webcast and conference call on Tuesday, November 7, 2017 at 8:00 a.m. EST to discuss its third quarter 2017 financial results and provide an update on recent clinical development and corporate
View HTML
Toggle Summary Acceleron Announces Closing of Underwriters' Option to Purchase Additional Shares
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that it has issued 810,810 shares of common stock at the public offering price
View HTML
Toggle Summary Acceleron Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics intended to treat serious and rare hematologic, neuromuscular, and pulmonary diseases, today announced that it has priced an
View HTML
Toggle Summary Acceleron Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare hematologic, neuromuscular, and pulmonary diseases, today announced that it intends to offer and sell,
View HTML
Toggle Summary Acceleron Showcases Vision and Strategy at 2017 R&D Day
- Clinical development and research efforts focused on hematological, neuromuscular and pulmonary diseases - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and
View HTML
Toggle Summary Acceleron to Develop Sotatercept in Pulmonary Arterial Hypertension
- Acceleron gains rights to fund, develop, and lead global commercialization of sotatercept in pulmonary arterial hypertension - - Acceleron expects to initiate a Phase 2 trial of sotatercept in pulmonary arterial hypertension in 1H 2018 - - Preclinical results show potential first-in-class disease
View HTML